



Status of Herbal Drugs in Cardiovascular Research: A Review

Ravinderpal Kaur *, Kushwah A.S , Parminder Kaur

Pharmacology and Toxicology Research Lab, Department of Pharmacology ASBASJSM College of Pharmacy, Bela (Ropar)-140111. Punjab (India)

.....
Abstract

Globally, cardiovascular diseases (CVD) constitute a leading cause of mortality. Heart disease in India occurs 10 to 15 years earlier than in the west. One fifth of the deaths in India are from coronary heart disease (CHD). The global burden of disease due to cardiovascular diseases (CVDs) is escalating, principally due to a sharp rise in the developing countries which are experiencing rapid health transition. More than 2000 plants have been listed in the Traditional (Herbal/Alternative) systems of medicine and some of these are providing comprehensive relief to the people suffering from cardiovascular diseases, specially “hyperlipidemia” and “ischemic heart disease”. WHO reports indicate that around eighty percent of the global population still relies on botanical drugs and several herbal medicines have advanced to clinical use in modern times. This review work explains chemical and pharmacological status of various cardioprotective plants including phytoconstituents responsible for cardioprotection, pharmacological screening model and mechanism involved in cardioprotection.

Keywords: Cardiovascular diseases, antioxidant, cardioprotective, phytoconstituents.
.....

1. INTRODUCTION

There is little doubt that Traditional Medicines have been utilized since antiquity in the health care. However, with the advent of the pharmaceutical industry early in this century, the popularity of traditional/herbal medicine

declined, in spite of the fact that twenty five percent of all prescription drugs still contain ingredients isolated from plants. The resources now do exist which can help and assist for greater understanding of the ways in which herbs can facilitate health and restore balance in disease¹.

Herbal medicine is increasingly gaining greater acceptance from the public and medical profession due to greater advances in understanding of the mechanisms by which herbs positively influence health and quality of life². A major portion of the global population in developing countries still relies on botanical drugs to meet its health needs. The attention paid by health authorities to the use of herbal medicines has increased considerably, both because they are often the only medicine available in less developed areas and because they are becoming a popular alternative treatment in more developed areas. Thus herbal medicines have been given a valuable status and readily available products for primary health care, and WHO has endorsed their safe and effective use³.

Cardiovascular diseases (CVDs) are the most prevalent cause of death and disability worldwide. CVD a group of disorders of the heart and the vasculature includes high blood pressure coronary heart disease, congestive heart failure, stroke and congenital heart defects. The world health organization (WHO) estimates that 17 million people die of cardiovascular disease annually. WHO

predicts that deaths due to circulatory system diseases are projected to double by 2015⁴. The synthetic drugs that constitute the current pharmacological armamentarium are themselves effective in managing the condition but not without setbacks. These hunches have accelerated the need for natural products with better efficacy and fewer side effects⁵.

More than 2000 plants have been listed in the Traditional (Herbal/Alternative) systems of medicine and some of these are providing comprehensive relief to the people suffering from cardiovascular diseases, specially “hyperlipidemia” and “ischemic heart disease”. WHO reports indicate that around eighty percent of the global population still relies on botanical drugs and several herbal medicines have advanced to clinical use in modern times⁶. Although, some traditional Chinese Medicines have been used in mainland, Hong Kong, Taiwan of China in clinics and other Chinese communities worldwide for centuries⁷. The use of Western medicinal drugs for the treatment of hypertension, congestive heart failure and post myocardial infarction are widely

accepted. For cardiovascular diseases, herbal treatments have been used in patients with congestive heart failure, systolic hypertension, angina pectoris, atherosclerosis, cerebral insufficiency, venous insufficiency and arrhythmia⁸.

Doubts have been raised for the use of herbal drugs on the reasons that (i) herbs of different origin are often known by the same popular name, (ii) plants growing in different climatic soil and seasonal conditions do not have identical chemical constituents or therapeutic effect, (iii) process of collection (fresh, shade or sun dried) extraction, processing and storage of herbal medicines cause variation in potency and safety, (iv) no specific standards for herbal medicines have been prescribed and (v) non availability of these herbal medicines in suitable dosage form created difficulty in administration. These shortcomings have delayed the integration of some of the well recognised Ayurvedic or Unani recipes in the modern system of medicine⁹.

2. HERBAL COMPOUNDS AS ANTIOXIDANTS:

Reactive oxygen species (ROS) including superoxide radicals, hydroxyl radicals, singlet oxygen and hydrogen

peroxide are often generated as byproducts of biological reaction or from exogenous factors¹⁰. *In vivo*, some of these ROS play an important role in cell metabolism including energy production, phagocytosis and intercellular signalling¹¹. However, these ROS produced by sunlight, ultraviolet light, ionizing radiation, chemical reactions and metabolic processes have a wide variety of pathological effects such as DNA damage, carcinogenesis and various degenerative disorders such as cardiovascular diseases, aging and neuro-degenerative diseases¹²⁻¹⁴.

Recent studies have shown that a number of plant products including polyphenols, terpenes and various plant extracts exerted an antioxidant action¹⁵⁻¹⁸. There is also a considerable amount of evidence revealing an association between individuals who have a diet rich in fresh fruits and vegetables and the decreased risk of cardiovascular diseases and certain forms of cancer^{19,20}. In recent decades, substantial interest has been focused on antioxidant therapeutic strategies for cardiovascular disease. It is imperative to emphasize effective preventive strategies for the cardiovascular disease epidemic. In

years past, vegetable, fruit and antioxidant-rich Mediterranean diets have been highlighted, since a number of epidemiological studies have shown a strong inverse relationship between cardiovascular disease and vegetable and fruit rich diets²¹. The World Health Organization recommends 500g of fresh fruits and vegetables per day²². Antioxidant micronutrients have attracted special attention, particularly vitamin E, vitamin C, beta carotene and other carotenoids, such as lutein, zeaxanthin and lycopene, which have the greatest singlet oxygen quenching properties²³. More recently, there has been increased interest in putative dietary antioxidants like bioflavonoids, flavonols like quercetin or special phenol derivatives in red wine and oxygen sensitive B complexes, which are involved in the metabolism of homocysteine and L-arginine^{24,25}. Flavonoids are effective antioxidants in plants as well as in animals²⁶. Flavonoids are identified as potential risk reducing components in the diet for cardiovascular disease, various cancers, neurodegenerative diseases, etc²⁷. For example, quercetin-3-O-glucoside, a flavonoid compound ubiquitous in fruits,

has shown protective effect on human neuroblastoma cells (SH-SY5Y) against oxidative stress by a membrane injury recovery mechanism that is involved in up-regulation of genes involved in lipid and cholesterol synthesis²⁸.

3. HERBAL COMPOUNDS AS ACE INHIBITORS:

Hypertension is the most common cardiovascular disease and a major public health problem in both developed and developing countries²⁹. A large number of population surveys from different parts of the globe have consistently demonstrated hypertension to be a ubiquitous disease encompassing all ethnic groups and geographic region^{30,31}. High blood pressure occurs when the body's smaller blood vessels (known as the arterioles) narrow, thereby causing the blood to exert excessive pressure against the vessel walls. The heart works harder to maintain higher blood pressure. Although the body can tolerate increased blood pressure for months and even years, eventually they enlarge and get damaged. Hypertension has been aptly called a silent killer, because it usually produces no noticeable symptoms. Hypertension is referred to as essential, or primary, when

the physical is unable to identify a specific cause. This is by far the most common type of high blood pressure, occurring in up to 95% of patients³². Herbal treatments are usually necessary. A single plant root can often control mild to moderate hypertension. More severe hypertension often requires a combination of two or more plant combination. In addition to helping lower blood pressure, herbal medicine provides health benefits³³.

Angiotensin converting enzyme (ACE) is a key component in the renin angiotensin aldosterone system (RAAS) which regulates blood pressure. As the over expression of RAAS is associated with vascular hypertension, ACE inhibition has become a major target control for hypertension. The research on potential ACE inhibitors is expanding broadly and most are focused on natural product derivatives such as peptides, polyphenolics, and terpenes. Plant polyphenolics are antioxidant molecules with various beneficial pharmacological properties³⁴. Some terpenoids and polyphenolic compounds including flavonoids, hydrolysable tannins, xanthenes, procyanidins, caffeoylquinic acid derivatives are found to be effective

as natural ACE inhibitors^{35,36}. Most studies have showed that plant extracts rich in phytochemicals found to be effective in ACE inhibition. However, identification of compounds specifically inhibit ACE is lacking in most of these investigations. Plant-derived peptides have been identified from different sources including soybean, flaxseed, sunflower, rice, and corn. Anthocyanins have shown ACE inhibition *in vitro*. Delphinidin-3-*O*-sambubiosides and cyanidin-3-*O*-sambubiosides isolated from Hibiscus (*Hibiscus sabdariffa*) extracts had inhibited ACE in a dose dependant manner³⁷. Similarly, cyanidin-3-*O*- β -glucoside isolated from rose species (*Rosa damascene*) inhibited ACE *in vitro*. However, other flavonols isolated from rose extract were not effective ACE inhibitors when compared to cyanidin-3-*O*- β -glucoside³⁸. Bilberry (*Vaccinium myrtillus*) extracts rich in major anthocyanins i.e. cyanidin, delphinidin and malvidin, were investigated on their effect on ACE in a human umbilical vein endothelial cell (HUVEC) culture model and the ACE activity had been significantly reduced after incubation of cells with bilberry extracts³⁹. The four major catechins, (–

-epicatechin, (-)-epigallocatechin, (-)-epicatechingallate and (-)-epigallocatechingallate, isolated from tea had also shown a dose dependant ACE inhibition in a HUVEC culture model⁴⁰. Pycnogenol, a procyanidin oligomer, isolated from French maritime pine (*Pinus maritime*) had also reported as an effective mediator for blood pressure regulation possibly by ACE inhibition⁴¹. These studies prove that among flavonoids, flavanols and procyanidins could also act as potent inhibitors of ACE *in vitro*.

4. HERBAL COMPOUNDS AS NADPH OXIDASE INHIBITORS :

Most estimates suggest that the majority of intracellular ROS production is derived from the mitochondria. The production of mitochondrial superoxide radicals occurs primarily through an enzyme NADPH oxidases. NADPH oxidases are a family of multi subunit enzyme complexes that are unique in being the only enzymes that have been identified with the primary function of generating superoxide and/or hydrogen peroxide. The primary catalytic function of the NADPH oxidase family of enzymes is the generation of ROS. The ROS generated by NADPH oxidases

have crucial roles in various physiological processes. Recently it has been emerged that excessive ROS production by an overactive NADPH oxidase system in vessel wall may set in motion a vicious cycle of radical and non-radical oxidant generation in various cellular compartments, which disrupts redox circuits^{42,43}. The naturally occurring methoxyphenol apocynin has been found to inhibit NADPH oxidase upon activation by peroxidases (e.g. soybean peroxidase, myeloperoxidase) or ROS under mild reaction conditions. Upon peroxidase-catalyzed activation, the apocynin oxidation products act to block the assembly and activation of NADPH oxidase. Although the mechanism of inhibition of NADPH oxidase remains largely unknown, apocynin's high effectiveness and low toxicity makes it a promising lead compound in the development of new therapeutic agents for cardiovascular diseases⁴⁴.

5. HERBAL COMPOUNDS AS PLATELET AGGREGATION INHIBITOR:

Platelet receptors on the surface of the platelets determine the reactivity of platelets and have a wide range of

agonists and adhesive proteins⁴⁵. Current antiplatelet therapies target key pathways of platelet activation, including surface receptors and signalling molecules. Aspirin has been the foundation of antiplatelet therapy for over 50 years, and it inhibits platelets by irreversibly acetylating Ser529 of cyclooxygenase 1 (COX1), thereby inhibiting thromboxane A2 formation by the platelets. Aspirin has been shown to reduce vascular death in high-risk patients by 15% and nonfatal vascular events by 30%, as evidenced by meta-analysis of over 100 randomized trials^{46,47}. Several medicinal plants have direct or indirect antiplatelet effects, many through inhibition of COX1 or 2. Likewise, a variety of fruit extracts have been tested *in vitro* for their antiplatelet property, and tomatoes have been found to have a very high activity⁴⁸. It was showed that tomato extract inhibited both ADP- and collagen induced aggregation by up to 70%. Various fruit juices have also been tested, and some flavonoids have been established as inhibitors of collagen-induced platelet activity^{49,50}. The effect of flavonoids is well established, and for coffee, it was showed that the caffeine is not the

inhibitor⁵¹ but rather the phenolics that was also found inside the platelets. Many of the effects observed are often due to synergistic effects, which are also seen on tomato and grape juice, and the effect can be expected to be lower for the individual compounds⁴⁸⁻⁵¹.

Garlic preparations are taken by many patients because of their anti-lipid and anti-platelet effects, significant factors in the prevention of thrombus formation⁵²⁻⁵⁴. The allicin derivative of garlic root has been shown to enhance fibrinolytic activity and inhibit platelet aggregation in patients with coronary artery disease⁵⁵⁻⁵⁷, either via a dose-dependent alteration in the production of arachidonic acid metabolites (i.e. inhibition of thromboxane formation in platelets^{56,58,59} or by altering physiochemical properties (i.e. the ADP-receptor) of the platelet membrane⁶⁰⁻⁶². Other herbs may also affect platelet function through inhibition of prostaglandin metabolism. Ginger, used by pregnant women for the relief of nausea and vomiting^{63,64}, reduces the production of PG-endoperoxides and thromboxane through either inhibition of platelet cyclooxygenase (COX)⁶⁵ or as a result of the anti-oxidant components in

the herb which suppress the lipid peroxide essential for COX activity^{66,67}. Feverfew, an herb used to treat migraine headaches⁶⁸⁻⁷⁰, suppresses upto 88% of prostaglandin production without inhibiting COX⁷¹⁻⁷⁵, while clove – a common kitchen spice and important source of dietary antioxidants⁷⁶, contains two antiplatelet components (eugenol and acetyl eugenol) which inhibit platelet thromboxane formation and increase formation of 12-HPETE, both of which are more potent than aspirin in their antiplatelet effects⁷⁷. Bromelain, a derivative of pineapple with immunomodulatory effects⁷⁸, also inhibits platelet prostaglandin synthesis⁷⁹, while the coumarin-containing herb licorice (with the 3-aryl coumarin derivative GU-7⁸⁰ inhibits COX, lip-oxygenase and peroxidase activity in platelets⁸¹.

Some herbs affect platelet function through other mechanisms. In addition to its anticoagulant effect, the Chinese herb Danshen inhibits platelet aggregation and release via increasing intracellular cyclic AMP⁸². Ginseng, a popular herb comprising 15–20% of the total annual sales of botanical products in the United States⁸³ (whose real benefits are still controversial⁸⁴, inhibits platelet

aggregation induced by thrombin or collagen in the rat model⁸⁵. Ginkgo biloba, use by Chinese doctors for centuries for the treatment of “chest complaints”, has been shown in clinical studies to be superior to placebo for intermittent claudication⁸⁶ and (questionably) beneficial for dementia as well^{87,88}. The increased risk for bleeding in patients using this herb is thought to be due to a dose-dependent inhibition of PAF-induced platelet aggregation⁸⁹. Red pepper (capsaicin), an herb used to alleviate diabetic neuropathy⁹⁰, inhibits platelet aggregation and release⁹¹, as well enhancing fibrinolytic activity⁹².

6. HERBAL DRUGS LOWERING CHOLESTEROL:

Hyperlipidemia (Elevated cholesterol or triglyceride) is a major cause of atherosclerosis and atherosclerosis associated conditions such as coronary heart disease, ischemic cerebrovascular disease and peripheral vascular disease. The lipid metabolism is regulated in many different ways. Enzymes are major regulators of lipid metabolism⁹³. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is one of the enzymes involved in cholesterol biosynthesis⁹⁴. There are several

antihyperlipidemic drugs available in market like statins, fibrates, niacin etc. Various herbal drugs are also potent antihyperlipidemic but their mechanism of action is still unclear. Some of these drugs are *Andrographis paniculata*, *Anthocephalus indicus*, *Ocimum sanctum*, *Picrorrhiza kurroa*, *Plumbago zeylanica*, *Terminalia arjuna*⁹⁵⁻¹⁰⁰. They might be acting through inhibition of HMGCoA Reductase.

Polyphenols are common constituents of botanical extracts available in over-the-counter nutraceutical preparations and are found in different fruits and vegetables, olive oil, and beverages like red wine and tea. Consumption of polyphenols in the diet has been shown to reduce the likelihood of morbidity and mortality from coronary artery disease¹⁰¹. One way in which polyphenols are thought to act is through the inhibition of lipid peroxidation of low-density lipoprotein (LDL)¹⁰². Dietary supplements rich in polyphenols, such as black and green tea¹⁰³, olive oil¹⁰⁴, red wine¹⁰⁵, and licorice root extract¹⁰⁶, are associated with an increased resistance of plasma LDL oxidation. Indeed, consumption of tea extract, red wine or licorice extract by

hyper-cholesterolemic apolipoprotein E (apoE)-deficient mice caused a significant reduction in atherosclerosis¹⁰⁶⁻¹⁰⁸.

Tsi *et al* studied the antihyperlipidaemic property of aqueous extract of celery, *Apium graveolans* Linn. (*Badi Ajmod*) in rats. A significant reduction was reported by them in the serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) concentrations in rats¹⁰⁹. The lipid lowering and antioxidant potential of ethanolic extract of adraka or ginger, *Zingiber officinale* Rosc. was evaluated in streptozotocin (STZ)-induced diabetes in rats by Bhandari *et al*. Ethanolic extract of ginger (200 mg/kg) fed orally for 20 days produced significant antihyperglycaemic effect ($P < 0.01$) in diabetic rats. Further, the extract treatment also lowered serum total cholesterol, triglycerides and increased the HDL cholesterol levels when compared with pathogenic diabetic rats¹¹⁰. The alcoholic extract of *Achyranthes aspera* Linn., at 100 mg/kg dose lowered serum cholesterol (TC), phospholipid (PL), triglyceride (TG) and total lipids (TL) levels by 60, 51, 33 and 53%, respectively in triton induced

hyperlipidaemic rats. The chronic administration of this drug at the same doses to normal rats for 30 days, lowered serum TC, PL, TG and TL by 56, 62, 68 and 67%, respectively followed by significant reduction in the levels of hepatic lipids¹¹¹. The lipid lowering activity (LLA) of *Phyllanthus niruri* Hook. f. Has been studied by Khanna and others in triton and cholesterol fed hyperlipemic rats. Serum lipids were lowered by *P. niruri* extract orally fed (250 mg/kg b.w.) to the triton WR-1339 induced hyperlipemic rats. Chronic feeding of this drug (100 mg/kg b.w.) in animals simultaneously fed with cholesterol (25 mg/kg b.w.) for 30 days caused lowering in the lipids and apoprotein levels of VLDL and LDL in experimental animals¹¹². The effects of the administration of 50 mg of

guggulipid of *Commiphora mukul* (Hook. ex Stocks) Engl. Or placebo capsules twice daily for 24 weeks were compared by Singh and others as adjuncts to a fruit- and vegetable-enriched prudent diet in the management of 61 patients with hypercholesterolaemia (31 in the guggulipid group and 30 in the placebo group) in a randomized, double-blind fashion. Guggul lipid decreased the total cholesterol level by 11.7%, the LDL-cholesterol by 12.5%, triglycerides by 12.0%, and the total cholesterol/ HDL-cholesterol ratio by 11.1% from the post diet levels, whereas the levels were unchanged in the placebo group¹¹³.

Some Herbal Cardioprotective Compounds: Table 1. Shows the various herbal Cardioprotective compounds¹¹⁴⁻¹⁴⁴.

S. No.	Plant name	Chemical compound	Model (<i>In-vivo</i> / <i>In-vitro</i>)	Activity
1)	<i>Cnidium monnieri</i> (Umbelliferae) ¹¹⁴	Osthol	Spontaneously hypertensive rat	Lowers blood pressure and cholesterol
2)	<i>Genista tinctoria</i> (Fabaceae) ¹¹⁵	Genistein	Spontaneously hypertensive rat	Up regulates nitric oxide synthase and lowers blood pressure.
3)	Various plants ¹¹⁶	Ursolic acid	Isolated perfused beating rabbit atria	Increase atrial natriuretic peptide secretion
4)	<i>Gingko biloba</i> (Gingkoaceae) ¹¹⁷	Bilobalide	Neonatal rat cardiomyocyte	Anti-ischemic

5)	<i>Ficus racemosa</i> (Moraceae) ¹¹⁸	Kaempferol	Aortic tissues of male wistar Kyoto rats.	ACE inhibition
6)	<i>Bacopa monnieri</i> (Scrophulariaceae) ¹¹⁹	Bacosides A and B	Isoproterenol induced myocardial necrosis in rats	Antioxidant
7)	<i>Cinnamomum tamala</i> (Lauraceae) ¹²⁰	Cinnamaldehyde	High Cholesterol Diet Induced Hyperlipidemia	Antihyperlipidemic
8)	Grape (Vitaceae) ¹²¹ activity	Resveratrol	Rat aortic homogenates	Decreases NADH/NADPH activity
9)	<i>Commiphora mukul</i> (Burseraceae) ¹²²	Guggulsterone isomers	Isoproterenol induced myocardial necrosis in rats (<i>in vivo</i>)	Inhibit oxidative degradation of lipids in human low-density lipoprotein <i>in vivo</i>
10)	<i>Mangifera indica</i> (Anacardiaceae) ¹²³	Mangiferin	Isoproterenol induced myocardial infarction in albino rats	Decrease lipid peroxide formation
11)	<i>Silybum marianum</i> (Compositae) ¹²⁴	Silymarin	Ischemia-reperfusion-induced myocardial infarction in albino rats	Protect the endogenous antioxidant enzymes, suppress the neutrophil infiltration during ischemia-reperfusion and limit the infarct size.
12)	<i>Daphne giraldii Nitsche</i> (Thymelaeaceae) ¹²⁵	Daphnetoxin, Gniditricin	-	Cholesterol lowering
13)	<i>Pinus maritime</i> (Pinaceae) ¹²⁶	Pycnogenol	Reduction of cardiovascular risk factors in subjects with type 2 diabetes	ACE inhibition
14)	Green tea ¹²⁷	Catechin, epigallocatechin	Murine pulmonary thrombosis	Antithrombotic
15)	<i>Sophora Japonica</i> (Fabaceae) ¹²⁸	Rutin	Anaesthetized rats subjected to coronary artery ligation	Reduce the infarct size and prevents the loss of the 'R' wave

16)	Various fruits ¹²⁹	Quercetin 3-O- glycosides	Human neuroblastoma cells(SH-SY5Y)	Antioxidant
17)	<i>Hibiscus sabdariffa</i> (<i>Malvaceae</i>) ¹³⁰	Delphinidi n-3-O- sambubiosi des and cyanidin-3- O- sambubiosi des	-	ACE Inhibition
18)	<i>Vaccinium myrtillus</i> (<i>Ericaceae</i>) ¹³¹	Cyanidin, delphinidin and malvidin	Human umbilical vein endothelial cell (HUVEC) culture model	ACE Inhibition
19)	<i>Hydrocotyle asiatica</i> (<i>Umbelliferae</i>) ¹³²	Asiatocosid e, madecass oside, madasiatic acid, cintella and fatty acid polyacetylene	Ischemia- reperfusion induced myocardial infarction in rats	Myocardial infarction
20)	<i>Ligustrum delavayanum</i> (<i>Oleaceae</i>) ¹³³	Iridoid glycosides, quercetin- 3-o-β-D- glucoside, quercetin- triglycoside , luteolin-7- o-β-D- glucoside, kempferol- 7-o- rhamnoside	Myocardial ischaemia- reperfusion injury in diabetic- hypercholesterole mia rats	Decrease cholesterol levels
21)	<i>Desmodium gangeticum</i> (<i>Fabaceae</i>) ¹³⁴	Protocatech uric acid, chlorogenic acid, gallic acid, rutin, quercetin,	Myocardial ischemia reperfusion injury in rat hearts	Antioxidant

		kaempferol, β -sitosterol, stigmasterol and lauric acid.		
22)	<i>Tinospora cordifolia</i> (Menispermaceae) ¹³⁵	Berberine and columbin.	Ischemia reperfusion induced myocardial infarction in rats.	Myocardial infarction
23)	<i>Crataeva nurvala</i> (Capparidaceae) ¹³⁶	Lupeol	Cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats.	In hyperlipidaemic cardiomyopathy
24)	<i>Sida rhomboidea</i> (Malvaceae) ¹³⁷	Cryptolepine, ephedrine, vasicine	Isoproterenol induced myocardial necrosis in rats	Myocardial necrosis
25)	<i>Eugenia uniflora</i> (Orchidaceae) ¹³⁸	Carotenoids, flavonoids	Rat thoracic aorta	Nitric oxide upregulation
26)	<i>Curcuma amada</i> (Zingiberaceae) ¹³⁹	Amadaldehyde	-	Platelet aggregation inhibitor
27)	<i>Allium sativum</i> (Liliaceae) ¹⁴⁰	Allicin	Rats fed with a high cholesterol diet	Reduces blood cholesterol, triglycerides levels and systolic blood pressure
28)	<i>Evodia rutaecarpa</i> (Rutaceae) ¹⁴¹⁻¹⁴⁴	Rutaecarpine	Guinea pig isolated right atria, presensitized guinea pig thoracic aorta challenged with antigen, human platelet-rich plasma, monocyte-like cell line THP-1 and promyelocytic leukemia cell line HL60.	Positive inotropic and chronotropic effects, inhibits vasoconstriction, inhibits platelet aggregation, anti-atherosclerosis

CONCLUSIONS:

It has been suggested that, for the future drug development, herbs may be an important source of new compounds which may have fewer side effects. The understanding of the precise pharmacological properties of herbals will definitely help the development of new drugs. The review summarizes the studies on the cardiovascular effects of various herbals, which provides extensive and strong evidence for the potential use of herbal drugs in the treatment of cardiovascular diseases.

REFERENCES

1. Murray MT. The Healing Power of Herbs (2nd Edition), Prima Publishing Murray MT and Pizzorno JE (1991). Atherosclerosis. In: *Encyclopedia of Natural Medicine* published by Prima Publishing, CA1991;156-170.
2. Fugh-Berman A. Herbs and Supplements in the prevention and treatment of cardiovascular disease. *Preventive Cardiology* 2000;1:24-32.
3. WHO Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. Published by World Health Organization, Regional Office for the Western Pacific, Manila 1993;1-10.
4. Vijaykumar M, Selvi V, Krishnakumari S. Efficacy of *Lagenaria siceraria*(mol) on lipid profile in isoproterenol induced myocardial infarction in wistar rats. *International journal of pharma and biosciences* 2010;1(4):295-300.
5. Upaganlawar Aman, Gandhi Hardik and Balaraman R. Isoproterenol Induced Myocardial Infarction; Protective role of natural products. *Journal of pharmacology and toxicology* 2011;6(1):1-17.
6. Mahmood ZA, Mohammad S, Mahmood SBZ, Karim MA. Herbal treatment for cardiovascular disease the evidence based therapy. *Pak. J. Pharm. Sci* 2010;23(1):119-124.
7. Sun J, Tan BK, Huang SH et al. Effects of natural products on ischemic heart diseases and cardiovascular system. *Acta Pharmacol Sin* 2000;23(12):1142-1151.
8. Mashour NH, Lin GI, Frishman WH. Herbal Medicine for the Treatment of Cardiovascular Disease. *Arch intern med* 1998;158(9):2226-2234.
9. S.S Gupta. Prospects and perspectives of natural plant products in medicine. *IJP* 1994;26(1):1-12.
10. Kikuzaki H, Nakatani N. Antioxidant effects of some ginger constituents.

- Journal of Food Science* 1993;58(6):1407-1410.
11. Ottolenghi A. Interaction of ascorbic acid and mitochondria lipids. *Arch. Biochem. Biophys* 1959;79:355-363.
 12. Gyamfi MA, Yonamine M, Aniya Y. Free radical scavenging action of medicinal herbs from Ghana *Thonningia sanguine* on experimentally induced liver injuries. *Gen. Pharmacol* 2002;32:661-667.
 13. Osawa T. Novel natural antioxidants for utilization in food and biological systems. In *Postharvest Biochemistry of plant Food-Materials in the Tropics*; Uritani, I., Garcia, V. V., Mendoza, E. M. Eds.; Japan Scientific Societies Press: Tokyo, Japan, 1994;241-251.
 14. Noda Y, Anzai-Kmori A, Kohono M et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectromoter system. *Biochem. Mol. Biol. Inter* 1997;42:35-44.
 15. Zhou YC, Zheng RL. Phenolic compounds and an analogue as superoxide anion scavengers and antioxidants. *Bioch. Pharm.* 1991;2:1177-1179.
 16. Quinn LA, Tang HH. Antioxidant properties of phenolic compounds in macadamia nuts. *J. Am. Oil Chem. Soc* 1996;73:1585-1588.
 17. Seymour TA, Li SJ, Morrissey MT. Characterization of a Natural Antioxidant from Shrimp Shell Waste. *J. Agri. Food. Chem* 1996;44:682-685.
 18. Prasad K, Laxdal VA, Yu M, Raney BL. Evaluation of hydroxyl radical scavenging property of garlic. *Mol. C. Bioch* 1996; 154:55-63.
 19. Salah N, Miller NJ, Paganga G et al. Polyphenolics flavonols as scavenger of aqueous phase radicals and as chain breaking antioxidants. *Arch. Biochem. Biophys* 1995;2:339-346.
 20. Hertog MGL, Sweetnam PM, Fehily A et al. Antioxidant flavonols and ischemic heart disease in a welsh population of 95 men: the caerphilly study. *Am. J. Clin. Nutr* 1997;65:1489-1494.
 21. Weisburger JH. Lifestyle, health and disease prevention, the underlying mechanisms. *Eur. J. Cancer Prev* 2002;11:1-7.
 22. NRC (National Research Council, USA). Committee on diet and health, implication for reducing chronic disease risk. National academy of sciences, Washington, DC 1989.
 23. Halliwell B and Gutteridge JMC. Free radicals in biology and medicine. 2nd

- edn., Clarendon Press, Oxford, UK 1989;266-271.
24. Hirvonen T, Pietnam P, Virtanen M et al. Intake of flavonols and flavones and risk of coronary heart disease in male smokers 2001; 12:62-67.
25. Hinderliter AL, Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease. *Curr Atheroscler Rep* 2003;5:506-513.
26. Croft KD. The chemistry and biological effects of flavonoids and phenolic acids. *Ann N Y Acad Sci* 1998;854:435-442.
27. Stevenson DE, Hurst RD. Polyphenolic phytochemicals - just antioxidants or much more? *Cell Mol Life Sci* 2007;64(22):2900-2916.
28. Soundararajan R, Wishart AD, Rupasinghe HPV et al. Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells *in vitro* against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. *J Biol Chem* 2008;284(4):2231-2245.
29. Benowitz NL. Antihypertensive agents. In Katzung BG, editor. *Basic & Clinical Pharmacology*. 8th Ed. New York: McGraw-Hill Lange. 2001;155-180.
30. Stergiou GS, Salgami EV. New European, American and International guidelines for hypertension management: Agreement and disagreement. *Expert Rev Cardiovasc Ther* 2004;2:359-368.
31. Achard JM, Fournier A, Mazouz H et al. Protection against ischemia. A physiological function of the renin-angiotensin system. *Biochem Pharmacol* 2001;62:261-71.
32. Slikkerveer LJ. Building bridge with traditional knowledge, Honolulu (Hawaii) Indigenous knowledge and Development Monitor 2001;9(2):32.
33. Fugh-Berman A. Herbs and Supplements in the prevention and treatment of cardiovascular disease. *Preventive Cardiology* 2000;1:24-32.
34. B.W. Nileeka Balasuriya and H.P. Vasantha Rupasinghe. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. *Functional Foods in Health and Disease* 2011;5:172-188.
35. Kang DG, Kim YC, Sohn EJ et al. Hypotensive effect of butein via inhibition of angiotensin converting enzyme. *Biol Pharm Bull* 2003;26(9):1345-1347.
36. Loizzo MR, Said A, Tundis R et al. Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated from *Ailanthus excels* (Roxb)

- (Simaroubaceae). *Phytother Res* 2007;21:32-36.
37. Ojeda D, Jiménez-Ferrer E, Zamilpa A et al. Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-*O*-sambubiosides from *Hibiscus sabdariffa*. *J Ethnopharmacol* 2010;127(1):7-10.
38. Kwon EK, Lee DY, Lee H et al. Flavonoids from the buds of *Rosa damascena* inhibit the activity of 3-hydroxy-3-methylglutaryl-coenzyme a reductase and angiotensin I-converting enzyme. *J Agric Food Chem* 2010;58(2):882-886.
39. Persson IAL, Persson K, Andersson RGG. Effect of *Vaccinium myrtillus* and its polyphenols on angiotensin-converting enzyme activity in human endothelial cells. *J Agric Food Chem* 2009;57(11):4626-4629.
40. Persson IA, Joseffsson M, Persson K, Anderson RG. Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells. *J Pharm Pharmacol* 2006;58(8):1139-1144.
41. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycongenol supplementation. *Nutr Res* 2008;28:315-320.
42. Jones DP. Radical-free biology of oxidative stress. *Am. J. Physiol. Cell Physiol* 2008;295:849-868.
43. Santos CX, Tanaka LY, Wosniak J and Laurindo FR. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. *Antioxid. Redox Signal* 2009;11:2409-2427.
44. Jingjing Yu, Michel Weïwer, Robert J. Linhardt and Jonathan S. Dordick. The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases. *Current Vascular Pharmacology*, 2008;6:204-217
45. KJ Clemetson. "Platelet receptors," in *Platelets*, A. D. Michelson, Ed. Academic Press, San Diego, Calif, USA, 2002; 65-85.
46. Baigent C, Sudlow C, Collins R, and Peto R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *British Medical Journal* 2002;324:71-86.

47. Guthikonda S, Lev E I, Patel R. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. *Journal of Thrombosis and Haemostasis* 2007;5(3):490-496
48. Dutta-Roy AK, Crosbie L, and Gordon MJ. Effects of tomato extract on human platelet aggregation in vitro. *Platelets* 2001;12(4):218–227
49. Keevil JG, Osman HE, Reed JD, and Folts JD. Grape juice, but not orange juice or grapefruit juice, inhibits human platelet aggregation. *Journal of Nutrition* 2000;130(1):53-56.
50. Wright B, Moraes LA, Kemp CF. Structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. *British Journal of Pharmacology* 2010;159(6):1312-1325.
51. Natella F, Nardini M, Belevi F. Effect of coffee drinking on platelets: inhibition of aggregation and phenols incorporation. *British Journal of Nutrition* 2008;100(6):1276-1282.
52. Ackerman RT, Mulrow CD, Ramirez G et al. Garlic shows promise for improving some cardiovascular risk factors. *Arch Intern Med* 2001;161:813-824.
53. Stevinson C, Pittle MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. *Ann Intern Med* 2000;133:420-429.
54. Bordia A. Effect of garlic on human platelet aggregation in vitro. *Atherosclerosis* 1978;30:355–360.
55. Bordia A, Bansal HC, Arora SK et al. Effect of the essential oils of garlic and onion on alimentary hyperlipemia. *Atherosclerosis* 1975;21:15-19.
56. Bordia A, Verma SK, Srivastava KC. Effect of garlic (*Allium sativum*) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. *Prostaglandins Leukot Essent Fatty Acids* 1998;58:257-263.
57. Mohammad SF, Woodward SC. Characterization of a potent inhibitor of platelet aggregation and release reaction isolated from *allium sativum* (garlic). *Thromb Res* 1986;44:793–806.
58. Makheja AN, Vanderhoek JY, Bailey JM. Inhibition of platelet aggregation and thromboxane synthesis by onion and garlic. *Lancet* 1979;1:781.
59. Lawson LD, Ransom DK, Hughes BG. Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial

- garlic products. *Thromb Res* 1992;65:141-156.
60. Apitz-Castro R, Cabrera S, Cruz MR et al. Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. *Thromb Res* 1983;32:155-169.
61. Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. *J Nutr* 2000;130:2662-2665.
62. Makheja AN, Bailey JM. Antiplatelet constituents of garlic and onion. *Agents Actions* 1990;29:360-363.
63. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. *Br J Anaesth* 2000;84:367-371.
64. Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev* 2003;(4):CD 000145.
65. Srivastava KC. Effect of onion and ginger consumption on platelet thromboxane production in humans. *Prostaglandins Leukot Essent Fatty Acids* 1989;35:183-185.
66. Bordia A, Verma SK, Srivastava KC. Effect of ginger (*Zingiber officinale* Rosc.) and fenugreek (*Trigonella foenumgraecum* L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. *Prostaglandins Leukot Essent Fatty Acids* 1997;56:379-384.
67. Srivastava KC. Isolation and effects of some ginger components of platelet aggregation and eicosanoid biosynthesis. *Prostaglandins Leukotr Med* 1986;25:187-198.
68. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. *Cephalgia* 1998;18:704-708.
69. Pittler MH, Vogler BK, Ernst E. Feverfew for preventing migraine. *Cochrane Database Syst Rev* 2000;(3):CD002286.
70. Ernst E, Pittler MH. The efficacy and safety of feverfew (*Tanacetum parthenium* L.): an update of a systematic review. *Public Health Nutr* 2000;3:509-514.
71. Makheja AN, Bailey JM. The active principle in feverfew. *Lancet* 1981;2:1054.
72. Heptinstall S, Groenewegen WA, Spangenberg P et al. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphhydryl groups. *J Pharm Pharmacol* 1987;39:45-65.

73. Biggs MJ, Johnson ES, Persaud NP et al. Platelet aggregation in patients using feverfew for migraine. *Lancet* 1982;2:776.
74. Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity invitro. *J Pharm Pharmacol* 1990;42:553-557.
75. Collier HO, Butt NM, McDonald-Gibson WJ, et al. Extract of feverfew inhibits prostaglandin biosynthesis. *Lancet* 1980;2:922-923.
76. Dragland S, Senoo H, Wake K et al. Several culinary and medicinal herbs are important sources of dietary antioxidants. *J Nutr* 2003;133:1286-1290.
77. Srivastava KC. Antiplatelet principles from a food spice clove (*Syzygium aromaticum* L). *Prostaglandins Leukot Essent Fatty Acids* 1993;48:363-372.
78. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. *Cell Mol Life Sci* 2001;58:1234-1245.
79. Morita AH, Uchida DA, Taussig SJ et al. Chromatographic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. *Arch Int Pharmacodyn Ther* 1979;239:340-350.
80. Tawata M, Yoda Y, Aida K et al. Anti-platelet action of GU-7, a 3-aryl coumarin derivative, purified from *Glycyrrhizae radix*. *Planta Med* 1990;56:259-263.
81. Tawata M, Aida K, Noguchi T et al. Anti-platelet action of isoliquiritigenin, an aldose reductase inhibitor in licorice. *Eur J Pharmacol* 1992;25:87-92.
82. Wang Z, Roberts JM, Grant PG et al. The effects of a medicinal Chinese herb on platelet function. *Thromb Haemost* 1982;48:301-306.
83. Murray MT. Panax ginseng. In: *The Healing Power of herbs*. Prima Publishing 1995; USA. pp 265-279.
84. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomized clinical trials. *Eur J Clin Pharmacol* 1999;55:567-575.
85. Yun YP, Do JH, Ko SR et al. Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextran-induced blood stasis in rats and human platelet aggregation. *J Ethnopharm* 2001;77:259-264.
86. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. *Am J Med* 2000;108:276-281.

87. Canter PH, Ernst E. Ginkgo biloba: a smart drug? A systematic review of controlled trials of the cognitive effects of ginkgo biloba extracts in healthy people. *Psychopharmacol Bull* 2002;36:108-123.
88. Le Bars PL, Katz MM, Berman N et al. A placebo controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. *JAMA* 1997;278:1327-1332.
89. Chung KF, McCusker , Page CP et al. Effect of a ginkgolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man. *Lancet* 1987;1:248-251.
90. Halat KM, Dennehy CE. Botanicals and dietary supplements in diabetic peripheral neuropathy. *J Am Board Fam Pract* 2003;16:47-57.
91. Wang JP, Hsu MF, Teng CM. Antiplatelet effect of capsacain. *Thromb Res* 1984;36:497-507.
92. Wasantapruek S, Poolsuppassit S, Pibolnukarintr O. Enhanced fibrinolytic activity after capsicum ingestion. *N Engl J Med* 1974;290:1259-1260.
93. Lee C, Olson P, Hevener A et al. PPAR α regulates glucose metabolism and insulin sensitivity. *Proceeding of the national academy of science* 2006;103(9):3444-3449.
94. Mayes P. and Botham K. *Bioenergetics and The metabolism of carbohydrates and lipids.* (Eds. Murray RK, Granner DK, Mayes PA and Rodwell VW.) Harper's Illustrated Biochemistry, 26th ed. McGraw Hill publishing house 2003;175-225.
95. Zuraini A, Aziah MR, Arifah AK et al. Aqueous Extract of *Andrographis paniculata* improve Lipid profile of rats Fed with High cholesterol diet. *International Journal of Pharmacology* 2006;2(1):45-49.
96. Kumar V, Khan MM, Khanna AK et al. Lipid Lowering Activity of *Anthocephalus indicus* Root in Hyperlipidemic Rats. *eCAM Advance Access* 2008;1-6.
97. Hussain EHMA, Jamil K. & Rao M. Hypoglycemic, Hypolipidemic and Antioxidant properties of Tulsi (*Ocimum sanctum* LINN.) on streptozotocin induced diabetes in Rats. *Indian Journal of Clinical Biochemistry* 2001;16(2):190-194.
98. Lee HS, Yoo CB & Ku SK. Hypolipemic effect of water extracts of *Picrorrhiza kurroa* in high fat diet treated mouse. *Fitoterapia* 2006;77:579-584.
99. Ram A. Effect of *Plumbago zeylanica* in Hyperlipidemic rabbits and its modification by Vitamin E. *Indian*

- Journal of Pharmacology* 1996;28:161-166.
100. Ram A, Lauria P, Gupta R et al. Hypocholesteremic effects of *Terminalia arjuna* tree bark. *Journal of Ethnopharmacology* 1997;55:165-169.
101. Hertog MG, Feskens PC, Hollman PC et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet* 1993;342:1007-1011.
102. Teissedre PL, Frankel EN, Waterhouse AL et al. Inhibition of *in vitro* human LDL oxidation by phenolic antioxidants from grapes and wines. *J Sci Food Agric* 1996;70:55-61.
103. Serafini M, Ghiselli A, Ferroluzzi A. Red wine, tea and antioxidants. *Lancet* 1994;344: 626.
104. Aviram M, Elias K. Dietary olive oil reduces low-density lipoprotein uptake by macrophages and decreases the susceptibility of the lipoprotein to undergo lipid peroxidation. *Ann Nutr Metab* 1993;37:75-84.
105. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. *Am J Clin Nutri* 1995;61:549-54.
106. Fuhrman B, Buch S, Vaya J et al. Licorice extract and its major polyphenol glabridin protect lowdensity lipoprotein against lipid peroxidation: *in vitro* and *ex vivo* studies in humans and in atherosclerotic apolipoprotein E-deficient mice. *Am J Clin Nutri* 1997;66:267-75.
107. Hayek T, Fuhrman B, Vaya J et al. Reduced progression of atherosclerosis in apolipoprotein-E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. *Arterioscler Thrombos Vascul Biol* 1997;17:2744-2752.
108. Miura Y, Chiba T, Tomita I et al. Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. *J Nutri* 2001;131:27-32.
109. Tsi D, Das NP and Tan BK. Effects of aqueous celery (*Apium graveolens*) extract on lipid parameters of rats fed a high fat diet. *Planta Med* 1995;61(1):18-21.
110. Bhandari U, Kanojia R and Pillai KK. Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia

- in diabetic rats. *J Ethnopharmacol* 2005;97(2):227-30.
111. Khanna AK, Chander R, Singh C et al. Hypolipidemic activity of *Achyranthus aspera* Linn. in normal and triton induced hyperlipemic rats. *Indian J Exp Biol* 1992;30(2):128-130.
112. Khanna AK, Rizvi F and Chander R. Lipid lowering activity of *Phyllanthus niruri* in hyperlipemic rats. *J Ethnopharmacol* 2002;82(1):19-22.
113. Singh RB, Niaz MA and Ghosh S. Hypolipidemic and antioxidant effects of *Commiphora mukul* as an adjunct to dietary therapy in patients with hypercholesterolemia. *Cardiovasc Drugs Ther* 1994;8(4):659-664.
114. Ogawa H , Sasai N , Kamisako T , Baba K. Effects of osthol on blood pressure and lipid metabolism in stroke-prone spontaneously hypertensive rats. *Journal of Ethnopharmacology* 2007;112:26-31.
115. Si H and Liu D. Soy phytoestrogen genistein up-regulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. *J Nutr* 2008;138(2):297-304.
116. Cui HZ, Wen JF, Choi HR et al. Ursolic acid increases the secretion of atrial natriuretic peptide in isolated perfused beating rabbit atria. *Eur J Pharmacol* 2011;25;653(1-3):63-69.
117. Maerz S, Liu CH, Guo W, Zhu YZ. Anti-ischemic effects of bilobalide on neonatal rat cardiomyocytes and the involvement of the platelet-activating factor receptor. 2011.
118. Balasuriya Nileeka BW and Rupasinghe Vasantha HP. Plant flavonoids as angiotensin converting enzyme inhibitors in regulation of hypertension. *Functional Foods in Health and Disease* 2011;5:172-188.
119. Nandave M, Ojha SK, Joshi S et al. Cardioprotective effect of *Bacopa monnieri* against Isoproterenol induced myocardial necrosis in rats. *International Journal of Pharmacology* 2007;3:385-392.
120. Dhulasavant V, Shinde S, Pawar M, Naikwade S. Antihyperlipidemic Activity of *Cinnamomum tamala* Nees. on High Cholesterol Diet Induced Hyperlipidemia. *Int.J. PharmTech Res* 2010;2:2517-2521.
121. Orallo F, Alvarez E, Camiña M et al. The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine

- consumption. *Mol Pharmacol* 2002;61(2):294-302.
122. Chander R, Rizvi F, Khanna AK, Pratap R. Cardioprotective activity of synthetic guggulsterone (e and z - isomers) in isoproterenol induced myocardial ischemia in rats: A comparative study. *Indian Journal of Clinical Biochemistry* 2003;18:71-79.
123. Prabhu S, Jainu M, Sabitha KE, and Devi CSS. Cardio protective Effect of *Mangiferin* on Isoproterenol induced myocardial infarction in rats. *Indian Journal of Experimental Biology* 2006;44:209-215.
124. Rao PR, Viswanath RK. Cardioprotective activity of silymarin in ischemia reperfusion-induced myocardial infarction in albino rats. *Exp Clin Cardiol* 2007;12:179-187.
125. Zhang Y, Zhang H, Hua S et al. Identification of two herbal compounds with potential cholesterol-lowering activity. *Biochem Pharmacol.* 2007;74(6):940-947.
126. Zibadi S, Rohdewald PJ, Park D, Watson RR. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycongenol supplementation. *Nutr Res* 2008;28:315-320.
127. Kang DG, Kim YC, Sohn EJ et al. Hypotensive effect of butein via inhibition of angiotensin converting enzyme. *Biol Pharm Bull* 2003;26(9):1345-1347.
128. Chopra K, Singh M. Involvement of oxygen free radicals in cardioprotective effect of rutin: A naturally occurring flavonoid. *Indian J Pharmacol* 1994;26:13-18.
129. Soundararajan R, Wishart AD, Rupasinghe HPV et al. Quercetin 3-glucoside protects neuroblastoma (SH-SY5Y) cells *in vitro* against oxidative damage by inducing sterol regulatory element-binding protein-2-mediated cholesterol biosynthesis. *J Biol Chem* 2008;284(4):2231-2245.
130. Ojeda D, Jiménez-Ferrer E, Zamilpa A et al. Inhibition of angiotensin converting enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from *Hibiscus sabdariffa*. *J Ethnopharmacol* 2010;127(1):7-10.
131. Persson IAL, Persson K, Andersson RGG. Effect of *Vaccinium myrtillus* and its polyphenols on angiotensin-converting enzyme activity in human endothelial cells. *J Agric Food Chem* 2009;57(11):4626-4629.

132. Pragada RR, Veeravalli KK, Chowdary KPR, Routhu KV. Cardioprotective activity of *Hydrocotyle asiatica* L. in ischemia-reperfusion induced myocardial infarction in rats. *Journal of Ethnopharmacology* 2004;93:105-108.
133. Adriana A, Pavol M, Pavel S et al. Effects of *Ligustrum delavayanum* Hariot. on cholesterol levels and arrhythmogenesis induced by myocardial ischaemia-reperfusion injury in diabetic-hypercholesterolaemic rats. *Environmental Toxicology and Pharmacology* 2008;26:255-258.
134. Kurian GA, Suryanarayanan S, Raman A, Padikkala J. Antioxidant effects of ethyl acetate extract of *Desmodium gangeticum* root on myocardial ischemia reperfusion injury in rat hearts. *Chinese Medicine* 2010;5:1-7.
135. Rajeswara Rao P, Kumar KV, Viswanath RK, Subbaraju VG. Cardioprotective activity of *Tinospora cordifolia* in ischemia reperfusion induced myocardial infarction in rats. *Biol Pharm Bull* 2005;28:2319-2319.
136. Sudharsan PT, Mythili Y, Sudhahar V, Varalakshmi P. Role of lupeol and its ester on cyclophosphamide-induced hyperlipidaemic cardiomyopathy in rats. *Journal of Pharmacy and Pharmacology* 2005;57:1437-1444.
137. Thounaojam MC, Jadeja RN, Ansarullah, Karn SS, et al. Cardioprotective effect of *Sida rhomboidea*. Roxb extract against isoproterenol induced myocardial necrosis in rats. *Et. and toxicologic pathology* 2011;63:351-356.
138. Wazlawik E, Da Silva MA, Peters RR et al. Analysis of the role of nitric oxide in the relaxant effect of the crude extract and fractions from *Eugenia uniflora* in the rat thoracic aorta. *J Pharm Pharmacol* 1997;49:433-437.
139. Policegandra RS, Rehna K, Jagmohan Rao L and Aradhya SM. Antimicrobial, antioxidant, cytotoxicity and platelet aggregation inhibitory activity of a novel molecule isolated and characterized from mango ginger (*Curcuma amada* Roxb.) rhizome. *J. Biosci.* 2010;35(2):231-240.
140. Ali M, Al-Qattan KK, Al-Enezi F et al. Effect of allicin from garlic powder on serum lipids and blood pressure in rats fed with a

- high cholesterol diet. 2000;62(4):253-259.
141. Kobayashi Y, Hoshikuma K, Nakano Y et al. The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of *Evodia*
142. *rutaecarpa*, on the guinea-pig isolated right atria: Possible involvement of vanilloid receptors. *Planta Med* 2001;67:244-248.
143. Yu J, Tan GS, Deng PY et al. Involvement of CGRP in the inhibitory effect of rutaecarpine on vasoconstriction induced by
- anaphylaxis in guinea pig. *Regul. Pep* 2005;125:93-97.
144. Sheu JR, Hung WC, Lee YM, Yen MH. Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from *Evodia rutaecarpa*. *Eur. J. Pharmacol* 1996;318:469-475.
145. Kim SJ, Lee SJ, Lee S et al. Rutaecarpine ameliorates bodyweight gain through the inhibition of orexigenic neuropeptides NPY and AgRP in mice. *Biochem. Biophys. Res. Commun* 2009;389:437-442.

Source of support: Nil, Conflict of interest: None Declared